Emerging genetic evidence supports this notion in MASLD, showing that variants like PNPLA3 and TM6SF2, while strongly associated with hepatic fat and fibrosis, do not independently increase CVD risk in the absence of metabolic syndrome (47–49). Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.